FreeTheAI

Tempus AI Presents Data on AI Pre-Screening Tool for Lung Cancer

MixedMedium impact
TEM$64.72 −9.01%

Tempus AI, Inc. (TEM) presented findings from a 60,459-case study evaluating an artificial intelligence pre-screening panel for advanced non-small cell lung cancer at ESMO 2026. The algorithm analyzes routine hematoxylin and eosin slide images and achieved over 80% sensitivity across 12 distinct biomarkers, with several individual targets reaching sensitivity above 90%.

Because the tool relies on standard pathology slides already used in clinical care, it can integrate directly into existing workflows to prioritize candidates for confirmatory testing. Tempus developed the tool alongside Pfizer to help clinicians identify high-priority cases faster. However, because the panel is intended to triage patients rather than replace existing diagnostic tests, near-term revenue potential remains limited. Shares of Tempus AI, Inc. Class A dropped 9.01% to 64.72 USD today.

Future commercial adoption will depend on prospective clinical validation, regulatory milestones, payer reimbursement decisions, and broader market uptake by pathology providers.

Key points

  • Tempus AI presented results from a 60,459-case study at ESMO 2026 for an AI lung cancer pre-screening tool.
  • The algorithm demonstrated over 80% sensitivity across 12 biomarkers using routine pathology slide images.
  • The developmental panel is designed to prioritize high-risk patients for confirmatory diagnostic testing.
  • Tempus AI conducted the pre-screening research in collaboration with Pfizer.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What did Tempus AI report about its lung cancer pre-screening tool?

Tempus AI reported that its AI-enabled pre-screening panel achieved over 80% sensitivity across 12 biomarkers in an analysis of 60,459 cases of advanced non-small cell lung cancer.

Is the Tempus AI lung cancer pre-screening tool commercially available?

The tool is currently in development. It is designed as a triage panel to prioritize patients for confirmatory testing rather than replacing existing diagnostic tests.

Who collaborated with Tempus AI on the lung cancer pre-screening panel?

Tempus AI developed and evaluated the pre-screening panel in collaboration with Pfizer.